Hass Corp. appears in FDA device records as a legal applicant rather than only as a brand name. The supplied filing snapshot contains one linked 510(k) record, K262523 for Amber Arte, with a substantial equivalence decision dated October 16, 2026, under product code EIH. A separate FDA clearance document from 2016 names Hass Corp. as the applicant for the Amber Mill Series and Amber Press Series. The company’s own published product pages describe a family of lithium disilicate-based materials and a glaze intended for finishing. [1][2][7][3]

The Amber Arte filing and its documented scope

The linked FDA record identifies K262523 as an Amber Arte 510(k) with a substantial equivalence decision on October 16, 2026, and product code EIH. The supplied collection counts one record in the 510(k) pathway and one SESE decision, and the smaller record sample likewise contains that single entry. These figures describe the filing snapshot only; they are not a measure of total company clearances, sales or safety performance. [1][2]

Hass Corp.’s published product page describes Amber Arte Universal Glaze as a finishing material applied in a light layer, with multiple gloss levels in one glaze and a fluorescent expression intended to approach natural tooth color. The same page states compatibility with Amber Mill, Amber Mill Direct and Rosetta, and shows the glaze applied to zirconia alongside a fluorescence test result. A separate HASS retail page lists Amber Arte Liquid with the same three feature statements and marks it as available soon. [3][5]

Earlier clearance naming the same applicant

An FDA substantial equivalence determination dated July 14, 2016 names Hass Corp. as the applicant for the Amber Mill Series and Amber Press Series under regulation 21 CFR 872.6660, porcelain powder for clinical use, Class II, product code EIH. The document concludes that the two series are substantially equivalent to the predicate devices based on testing results. It is a dated submission example, not a statement about current portfolio size. [7]

The company’s own site lists Amber Press, Amber Press Master, Rosetta SM, Rosetta SP, Amber Mill, Amber Mill Direct and Amber Arte Glaze Value up among its products, describing the Amber Mill entries as lithium disilicate-based CAD/CAM blocks and disks and the Rosetta entries as lithium disilicate glass-ceramic materials. These descriptions come from the manufacturer’s published pages, not from FDA records. [4]

Corporate identity and published locations

A third-party device directory lists Hass Corp. as a South Korean manufacturer registered with FDA, with two registered establishments in South Korea, six 510(k) clearances as applicant from 2010 to 2026, and registrations in three markets. That directory’s counts differ from the single linked record in the filing snapshot and reflect its own data cut; neither figure should be read as total company sales or portfolio size. [6]

HASS’s published contact information lists a Gangneung headquarters, an R&D sales address in Gwangmyeong, a U.S. corporation address in Fairfax, Virginia, a European liaison office in Eschborn, Germany, and a Chinese subsidiary in Shanghai. These are addresses published by the manufacturer for its own offices; FDA filing addresses in the 2016 determination are correspondence addresses and are not treated here as headquarters. [5][7]

What the records do and do not establish

The records establish that Hass Corp. is the named FDA applicant on K262523 and on K160102, and that its published materials cover lithium disilicate-based press ingots, CAD/CAM blocks and disks, glass-ceramic blocks and ingots, and the Amber Arte glaze line. The records do not establish ownership of any parent company, customer relationships, clinical outcomes or commercial availability beyond the manufacturer’s own statements. [1][7][4][3]